Relax(in) your way to keep the cardiac diseases at bay: Relaxin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  Relaxin, a reproductive hormone,  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down-regulation of its target gene, 17/August/2018, 11.19 pm

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: PCGF2/Mel-18 increases the expression of tumor suppressors genes, such as  TIMP3, CCM3/KRIT1, p53, TAp63, TAp73, INK4a/ARF, and others, induces regression of p53-mutated human tumors, via down-regulation of its target gene, 17/August/2018, 10.55 pm
August 17, 2018
A drug used to treat angina may lengthen lifespan: Ranolazine-based therapy for life-span extension: Ranolazine (trade name: Ranexa) may  increase insulin sensitivity, slow down cardiac aging, and increase lifespan, via up-regulation of BubR1 and others genes, 17/August/2018, 11.36 pm
August 17, 2018
Show all

Introduction: What they say

A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April  2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20.761)by Prof Tzahor E, D’Uva E, and others.


What we say: 

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Relax(in) your way to keep the cardiac diseases at bay: Relaxin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  Relaxin, a reproductive hormone, increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down-regulation of its target gene


From the significance of the study to Public health relevance: 

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the rise in death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs and (iv) a side-effect-free Natural product-based drug.


From research findings to Therapeutic opportunity: 

This study suggests, for the first time, provides detailed mechanistic insights into how the reproductive hormone Relaxin may protect against cardiovascular diseases. Relaxin, by increasing the expression of its target gene, it may: (1) increase ERBB2/Her2 expression; (2) induce cardiomyocyte (CM) dedifferentiation and proliferation, and (3) cardiomyocyte (CM) redifferentiation and regenerationThus, pharmacological formulations encompassing “Relaxin or its recombinant versions, either alone or in combination with other drugs, may be used to treat cardiac dysfunction. 

Figure1. Mechanistic insights into how Relaxin may promote cardiac dedifferentiation and regeneration. Relaxin, by increasing the expression of its target gene, it may upregulate the expression of ERRB2/HER2 and promote cardiac dedifferentiation and regeneration

Figure 2. Relaxin may promote cardiac regeneration through induction of Her2/Erbb2

 

 

 

 

 

 

 

 

 

Given the mechanistic basis of how Relaxin may aid in cardiomyocyte survival and regeneration medical practitioners and cardiologists may consider treating myocardial patients with relaxin or its mimic (Serelaxin(recombinant human relaxin)-brand name: Reasanz), as it may aid in cardiomyocyte regeneration following myocardial infarction

[easy_payment currency=”USD”]


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $ 500#

Undisclosed (mechanistic insights) information: How does Relaxin increase the expression of  ERBB2/Her2?

For purchase and payment details, you may reach us at admin@genomediscovery.org

# Research cooperation


References: 

Web: http://genomediscovery.org or newbioideas.com

Citation: Boominathan, L.,  Relax(in) your way to keep the cardiac diseases at bay: Relaxin-based Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  Relaxin, a reproductive hormone,  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down-regulation of its target gene, 17/August/2018, 11.19 pm,  Genome-2-BioMedicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite, drop us a line at info@genomediscovery.org

Comments are closed.